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Despite the dramatic decline in human
immunodeficiency virus type 1 (HIV-1)-
related morbidity and mortality following
the discovery of the protease inhibitors and
the advent of combination highly active
antiretroviral (ARV) therapy in the mid-
1990s, many patients were still failing ther-
apy due to resistance and/or intolerability
(1). It was clear that more ARVs acting on
different steps in the virus lifecycle, active
against resistant viruses, and better toler-
ated were needed. The demonstration of
the key role of the chemokine receptors
CCR5 and CXCR4 in HIV-1 entry sparked
interest in this process as a new ARV tar-
get (2, 3). CCR5 is the co-receptor for
the majority of HIV-1 strains, and these
viruses are termed CCR5 tropic (R5). Virus
strains that use CXCR4 are called CXCR4-
tropic (X4), while strains that can use both
receptors are dual-tropic (4). Virus from
a patient can often contain mixtures of
R5, X4, and dual-tropic strains, collectively
called CXCR4-using.
The key role of CCR5 in HIV-1 entry,
coupled with the demonstration that indi-
viduals who were homozygous for a 32
base pair deletion in the CCR5 gene
(CCR5∆32), and subsequently do not
express functional CCR5, were highly pro-
tected from infection with R5 HIV-1,
focused attention on CCR5 as an attrac-
tive target (5). Although some studies
have demonstrated subtle effects of the
CCR5∆32 mutation on immune function,
such as decreased inflammatory scores in
hepatitis C-infected individuals and recov-
ery from hepatitis B in heterozygotes; while
homozygotes are more susceptible to tick-
borne encephalitis and severe West Nile
virus disease, these individuals suffer lit-
tle apparent adverse effects on their health
(5, 6). This, together with the fact that
members of the G protein-coupled recep-
tor superfamily are often tractable to devel-
opment of potent, selective, and orally
bioavailable drugs (7), led to the initia-
tion of CCR5 ligand discovery programs
by multiple groups, including a team from
Pfizer Global Research and Development
based at the Sandwich laboratories in the
United Kingdom.
Maraviroc (UK-427,857, MVC) was dis-
covered through high-throughput screen-
ing of the Pfizer compound library using
a chemokine radioligand-binding assay.
The most promising compound from
the screening process was optimized for
potency against the receptor, antiviral
activity, pharmacokinetic characteristics,
and selectivity against human cellular tar-
gets through a large medicinal chemistry
effort in which almost 1000 molecules were
characterized (7). MVC binds in the trans-
membrane pocket of CCR5 and is a slow-
offset functional antagonist that prevents
internalization (7, 8). It has potent antivi-
ral activity against a wide-range of HIV-1
isolates (7). Together with its excellent pre-
clinical safety profile and acceptable phar-
macokinetics, this resulted in it being nom-
inated as a clinical candidate in December
2000 (7).
It was always clear that the clinical devel-
opment of CCR5 antagonists would be
challenging, as these would be the first
host-targeted ARV drugs and we were
therefore venturing into uncharted terri-
tory. In order to pre-empt key issues, a
clinical development team was established
very soon after the start of the discovery
program and I was recruited to lead the
early development team, joining Pfizer in
February 1999. We identified several key
challenges to address in the design of the
clinical program, in addition to demon-
strating safety and efficacy. The first of
these was that no commercially available,
clinically validated assay to identify patients
infected with R5 HIV-1 existed. This was
critical, as MVC is active only against R5
HIV-1 strains (7). Secondly, in spite of
the apparently healthy phenotype of indi-
viduals with CCR5∆32 (5, 6), concerns
remained regarding the safety of long-term
exposure to CCR5 antagonists, as blocking
of CCR5 may be different from congen-
ital absence of the CCR5 receptor, where
the immune system has matured in the
absence of CCR5 and compensatory mech-
anisms may have developed. Finally, in
HIV-1 infected individuals, the incidence
of CXCR4-using HIV-1 strains increases
with disease progression and decrease in
CD4 cell counts (9), although no causal link
between CXCR4-using virus and CD4-cell
depletion has been demonstrated. This has
led to concerns that selective pressure from
a CCR5 antagonist may drive the virus pop-
ulation to use CXCR4 and result in CD4 cell
decline.
Phase 1 single and multiple dose stud-
ies in healthy volunteers, conducted in
2001 and the first half of 2002, demon-
strated that MVC was safe and well-
tolerated in multiple doses up to 300 mg
twice a day (BID), had a pharmacoki-
netic profile compatible with once daily
(QD) or BID oral dosing, could be com-
bined with other ARVs, and that doses of
≥100 mg BID resulted in exposure above
the geometric mean antiviral IC90 in vitro
(7, 10). To demonstrate proof of phar-
macology, CCR5 receptor saturation was
measured using a bespoke ex vivo MIP-
1β internalization assay. Dose-dependent
www.frontiersin.org June 2015 | Volume 6 | Article 277 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Van Der Ryst CCR5 antagonist to treat HIV-1
saturation was demonstrated, with doses
of ≥25 mg QD resulting in near maxi-
mum saturation levels, raising the inter-
esting possibility that MVC could be effi-
cacious in doses as low as 25 mg QD.
Receptor saturation remained high for sev-
eral days after dosing was discontinued,
reflecting slow offset from the receptor
in vivo (11).
We were both excited and encouraged
by the phase 1 data and rapidly moved on
to a phase 2a proof of concept program.
HIV-1 infected patients were screened for
the presence of R5 virus only, using a novel
phenotypic tropism assay (Trofile®, Mono-
gram Biosciences, South San Francisco, CA,
USA), and received MVC as monotherapy
for 10 days (12). CCR5 receptor satura-
tion was measured in this study to evaluate
the possibility of using this as a biomarker
for efficacy and in therapeutic monitoring.
The keenly awaited data lived up to our
expectations and demonstrated that doses
of ≥100 mg BID resulted in mean maxi-
mum HIV-1 RNA reductions of >1.5log10
(Figure 1A), with all patients, excluding
one patient with X4 virus who has been
erroneously included, achieving an HIV-
1 RNA reduction of at least 1log10 (12).
This gave us confidence that the assay cor-
rectly identified patients likely to respond
to MVC. HIV-1 RNA nadir occurred 1–
5 days after the last dose of MVC, consis-
tent with prolonged receptor saturation as
demonstrated in the phase 1 studies (12).
For all doses except 25 mg QD receptor
saturation of>80% was observed through-
out the dosing period. However, there was
no correlation between viral load reduc-
tion and degree of receptor saturation.
The most likely explanation for this is
that very high levels of receptor saturation
is required for antiviral efficacy and the
inherent variability of the assay does not
allow differentiation to that degree (11, 12).
The phase 2a data generated excitement
throughout the company and we were keen
to progress the clinical development pro-
gram as quickly as possible as there was
a high medical need for new ARVs to
treat patients with no or limited treatment
options. The extensive phase 1 program
(including multiple drug-drug interaction
studies) and wide dose range evaluated
in the phase 2a proof of concept stud-
ies, together with modeling and simulation,
gave us a very good understanding of the
FIGURE 1 | Maraviroc proof of concept and phase 3 efficacy results. (A) Mean maximum change
from baseline in HIV-1 RNA in patients receiving MVC monotherapy. Based on phase 1 data and
modeling and simulation, doses ranging from 25 mg QD to 300 mg BID (including 150 mg BID fed and
fasted) were selected. HIV-1 RNA, safety, and MVC pharmacokinetics were evaluated (12).
(B) MOTIVATE 1 and 2 – proportion of patients achieving HIV-1 RNA <50 copies/mL at week 48. HIV-1
infected patients with R5 HIV-1 and triple class experience and/or resistance were randomized to
receive MVC QD or BID, or placebo, in combination with an optimized background antiretroviral regimen
(OBT). P <0.001 (13, 14).
likely efficacious dose of MVC in combina-
tion with other ARVs. We were therefore
able to move straight to phase 3 effi-
cacy studies evaluating MVC at 300 mg (or
equivalent, depending on co-administered
drugs) QD and BID, without the need to do
stand-alone phase 2b dose-ranging studies,
thereby significantly shortening the devel-
opment timeline. In late 2004, we initi-
ated four large studies; MOTIVATE 1 and
2 in treatment-experienced patients with
R5 HIV-1 (13, 14), MERIT (a phase 3
study with a phase 2b roll-in) in treatment-
naïve patients with R5 HIV-1 (15), and
study A4001029, a phase 2b safety study
in treatment-experienced patients with
non-CCR5 tropic virus (CXCR4-using or
non-phenotypable virus) (16).
This was a massive undertaking, with
4794 patients screened at more than 200
sites in the USA, Canada, Europe, Aus-
tralia, South Africa, Mexico, and Argentina.
Two other small molecule CCR5 antago-
nists (aplaviroc and vicriviroc) were also
being evaluated in phase 2b studies at this
time (17, 18). In addition to the usual
challenges of managing large clinical stud-
ies, we were thrown two curveballs, the
first of these were the discontinuation of
aplaviroc due to idiosyncratic hepatotoxic-
ity. There was speculation that this could
be a class effect of CCR5 antagonists as
CCR5 knockout mice are more suscepti-
ble concanavalin-A mediated hepatoxicity
(17). Additionally, a patient in the MERIT
study developed severe hepatotoxicity. The
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data implied that it was likely related to
isoniazid or cotrimoxazole, but a contribu-
tory role for MVC could not be excluded
(15). An in-depth review of all data for
evidence of hepatotoxicity for MVC and
a high level of vigilance for any signals,
did not find any evidence for a system-
atic increase in hepatic enzymes or other
markers for hepatotoxicity. Shortly after-
wards concerns were raised regarding a
potential increased risk for certain malig-
nancies, following the occurrence of lym-
phoma in four patients receiving vicriviroc
in study ACTG5211 (18). Initially there
were concerns that this could be a class-
effect based on the immune-modulatory
potential of CCR5 antagonists, but review
of data from other vicriviroc studies, as
well as the ongoing MVC studies did not
support this theory (18).
Data from MOTIVATE 1 and 2 and
A4001029 were available ahead of that
of MERIT, as study duration is typi-
cally shorter for studies in treatment-
experienced patients. It was with great
excitement that we awaited the week 24
interim analyses for the MOTIVATE stud-
ies in October 2006 and we were elated
to see that significantly more patients
receiving MVC had an HIV-1 RNA of
<50 copies/mL (the key marker for effi-
cacy) compared to those receiving placebo
OBT. This was confirmed by the week 48
data, demonstrating durability of response
(Figure 1B) (13, 14). In contrast, patients
with non-CCR5 tropic HIV-1 receiving
MVC in A4001029 did not appear to
gain significant virologic benefit compared
to placebo (16). Analysis of safety data
raised no significant concerns. Specifically,
there was no evidence of an adverse effect
on immune function, with no increase
in episodes of infection or malignancies
in MVC treated patients. Assessment of
virus tropism at failure demonstrated that
>50% of patients failing MVC therapy had
CXCR4-using virus at failure, but there
was no evidence of a deleterious effect
on CD4 cell count numbers (14). Viro-
logic assessment demonstrated that the
CXCR4-using virus that emerged under
MVC selective pressure was from a pre-
existing minority population and did not
arise de novo (19). Altogether, these results
clearly demonstrated the benefit of MVC in
the management of treatment-experienced
patients with R5 HIV-1. A supreme effort
by the team resulted in submission of
dossiers for registration in both the USA
and Europe only 2 months after the interim
data became available. MVC (300 mg BID)
received approval for use (in combination
with other ARVs) in the USA in August
2007, only 6.5 years after it was nominated
as a candidate for clinical development.
One month later, it was also approved for
use in this population in the EU.
The week 48 analysis of the MERIT
study was disappointing, as MVC plus
zidovudine/lamivudine (HIV-1 RNA <50
copies/mL, 65.3%) did not meet the
pre-set criteria for non-inferiority (lower
bound of the 1-sided 97.5 confidence
interval below −10%) to efavirenz plus
zidovudine/lamivudine (HIV-1 RNA <50
copies/mL, 69.3%) (15). However, patients
for this study were screened for R5 virus
using the original Trofile assay. This assay
has been improved in the meantime to
be more sensitive for the detection of
minority populations of CXCR4-using
virus. All screening samples for patients in
MERIT were subsequently retested using
the enhanced assay and a post hoc analy-
sis performed including only patients who
had R5 virus only by the more sensi-
tive assay. In this analysis the response
rates for MVC and efavirenz were 68.3
and 68.5%, respectively, with the lower
bound of the 97.5% confidence inter-
val above −10% (15). Based on this
data, MVC was also approved for use
in treatment-naïve patients in November
2009 by the United States Food and Drug
Administration.
MVC has not only proved to be a valu-
able addition to the ever growing ARV drug
armamentarium, but data from these stud-
ies have improved our understanding of
HIV tropism and the relationship between
tropism and disease progression. For me,
personally this represented a period of
great excitement and satisfaction, both as
a physician and scientist.
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